Novo Nordisk falls 4.2% as Wegovy sales disappoint

Reuters··DKGB·Read original
3▲0 ▼2Impact / 5
Summary · why it matters

Drugmaker Novo Nordisk, one of Europe's biggest companies by market value, was down 4.2% after disappointing sales of its Wegovy weight-loss pill overshadowed a strong second-quarter earnings beat. The decline came amid a broader rise in world stocks, with the pan-European STOXX 600 index up 0.3% and MSCI's broadest index of world shares gaining 0.4%. HSBC shares fell nearly 3% a day after its results as investors digested analysts' reactions. Meanwhile, AI-related stocks showed mixed performance, with AMD dropping 7% in premarket trading and SpaceX down 10% on capital spending concerns.

Impact on assets 4

Longevity & Life Extension▼ · 1 stocks
Novo Nordisk A/S
NVO
▼ NegativeDemandrelevance

Disappointing sales of Wegovy weight-loss pill overshadowed strong Q2 earnings beat.

Financials▼ · 1 stocks
HSBC Holdings PLC
HSBA
▼ NegativeCapitalrelevance

HSBC shares fell nearly 3% after results as investors digested analysts' reactions.

Artificial Intelligence▲ · 1 stocks
Space Economy▲ · 1 stocks
© 2026 MarketIVNews